公开(公告)号：US11932675B2

公开(公告)日：2024-03-19

申请号：US17067508

申请日：2020-10-09

申请人： Genentech, Inc. ,  Xencor, Inc.

发明人： John Desjarlais ,  Matthew Bernett ,  Michael Hedvat ,  Rajat Varma ,  Suzanne Schubbert ,  Christine Bonzon ,  Rumana Rashid ,  Juan Diaz ,  Patrick Holder ,  Christine Huang

IPC分类号： C07K14/00 ,  A61P35/00 ,  C07K14/54 ,  C07K16/28 ,  A61K38/00

CPC分类号： C07K14/5443 ,  A61P35/00 ,  C07K16/2818 ,  A61K38/00 ,  C07K2319/30

摘要： The present invention relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antigen binding domains, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antigen binding domains. The present invention also relates to nucleic acid molecules, expression vectors, host cells and methods for making such fusion proteins and the use of such fusion proteins in the treatment of cancer.

公开(公告)号：US11851466B2

公开(公告)日：2023-12-26

申请号：US17062458

申请日：2020-10-02

申请人： Xencor, Inc.

发明人： Matthew Bernett ,  John R. Desjarlais ,  Rajat Varma ,  Ke Liu ,  Rumana Rashid ,  Nargess Hassanzadeh-Kiabi ,  Michael Hedvat

IPC分类号： C07K16/46 ,  C07K14/54 ,  A61P35/00 ,  C07K16/28 ,  A61K39/00

CPC分类号： C07K14/5434 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2039/505 ,  C07K2317/622 ,  C07K2319/30

摘要： The present invention relates to targeted IL-12 heterodimeric Fc fusion proteins, where the fusion proteins bind to human PD-1 or human PD-L1.

公开(公告)号：US20230220081A1

公开(公告)日：2023-07-13

申请号：US18065462

申请日：2022-12-13

申请人： Xencor, Inc.

发明人： Matthew Bernett ,  Rumana Rashid ,  John Desjarlais ,  Rajat Varma ,  Christine Bonzon

IPC分类号： C07K16/28 ,  C07K14/54 ,  C07K14/715 ,  C12N15/63 ,  A61P35/00 ,  A61K39/00 ,  A61K38/00

CPC分类号： C07K16/2818 ,  C07K14/5443 ,  C07K14/7155 ,  C12N15/63 ,  A61P35/00 ,  C07K2317/24 ,  C07K2317/524 ,  A61K2039/505 ,  C07K2317/94 ,  C07K2319/30 ,  C07K2317/73 ,  C07K2317/526 ,  C07K2317/35 ,  C07K2317/92 ,  C07K2317/31 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/74 ,  A61K38/00 ,  C07K2319/32

摘要： The present invention is directed to novel bispecific heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein.

公开(公告)号：US20220380462A1

公开(公告)日：2022-12-01

申请号：US17339774

申请日：2021-06-04

申请人： Xencor, Inc.

发明人： Gregory Moore ,  Matthew Bernett ,  Rumana Rashid ,  John Desjarlais

IPC分类号： C07K16/28

摘要： The present invention is directed to optimized anti-CD3 variable sequences for use in a variety of bispecific formats, including those that utilize scFv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector. In another aspect, the invention provides for a pharmaceutical composition comprising the mentioned polypeptide and medical uses of the polypeptide.

公开(公告)号：US11377477B2

公开(公告)日：2022-07-05

申请号：US16600236

申请日：2019-10-11

申请人： Xencor, Inc.

发明人： Matthew Bernett ,  John R. Desjarlais ,  Michael Hedvat ,  Suzanne Schubbert ,  Christine Bonzon ,  Rumana Rashid ,  Rajat Varma

IPC分类号： C07K16/28 ,  A61K39/395 ,  C07K14/28 ,  C12N15/63 ,  C07K14/54 ,  A61K38/00

摘要： The present invention is directed to novel PD-1 targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein. In some embodiments, the PD-1 targeted IL-15/Rα-Fc fusion proteins are administered to a patient to treat cancer. In some embodiments, the PD-1 targeted IL-15/Rα-Fc fusion proteins are administered in combination with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab. In some embodiments, the PD-1 targeted IL-15/Rα-Fc fusion proteins do not compete with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab for antigen binding.

公开(公告)号：US11358999B2

公开(公告)日：2022-06-14

申请号：US16592656

申请日：2019-10-03

申请人： Xencor, Inc.

发明人： Matthew Bernett ,  John R. Desjarlais ,  Rajat Varma ,  Ke Liu ,  Nargess Hassanzadeh-Kiabi ,  Rumana Rashid

IPC分类号： C07K14/54 ,  C07K19/00 ,  C07K1/18 ,  A61K38/20 ,  A61K38/00

摘要： The present invention provides novel IL-12 Fc fusion proteins, methods of making and using the same. The IL-12. Fc fusion proteins are useful for treatment of cancer and can be used in combination with checkpoint blockade.

公开(公告)号：US11319355B2

公开(公告)日：2022-05-03

申请号：US16206849

申请日：2018-11-30

申请人： Xencor, Inc.

发明人： Matthew Bernett ,  John Desjarlais ,  Rajat Varma ,  Rumana Rashid

IPC分类号： C07K14/55 ,  C07K14/735 ,  C12N15/85 ,  A61K38/00

摘要： The present invention provides IL-2-Fc fusion proteins comprising IL-2 variants.

公开(公告)号：US20210163627A1

公开(公告)日：2021-06-03

申请号：US16918922

申请日：2020-07-01

申请人： Xencor, Inc.

发明人： Gregory Moore ,  Matthew Bernett ,  Rumana Rashid ,  John Desjarlais

IPC分类号： C07K16/46 ,  C07K16/28

摘要： The invention provides novel heterodimeric proteins including heterodimeric antibodies.

公开(公告)号：US10752678B2

公开(公告)日：2020-08-25

申请号：US15943192

申请日：2018-04-02

申请人： Allergan, Inc. ,  Xencor, Inc.

发明人： Peter C. Baciu ,  Yanbin Liang ,  Jason Guu ,  Matthew Bernett ,  Umesh Muchhal ,  John Desjarlais

IPC分类号： C07K16/18 ,  A61K39/395 ,  A61K39/00

摘要： The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies.

公开(公告)号：US10738133B2

公开(公告)日：2020-08-11

申请号：US15589908

申请日：2017-05-08

申请人： Xencor, Inc.

发明人： Gregory Moore ,  Matthew Bernett ,  Rumana Rashid ,  John Desjarlais

IPC分类号： C07K16/00 ,  C07K16/46 ,  C07K16/28

摘要： The invention provides novel heterodimeric proteins including heterodimeric antibodies.